PhIN: A protein pharmacology interaction network database

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 3, 2015, Pages 160-166

  Wang, Z ^a   Li, J ^a,b   Dang, R ^a   Liang, L ^a,b   Lin, J ^a,b  

^a NANKAI UNIVERSITY   (China)

^b Tianjin International Joint Academy of Biomedicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR SCAFFOLD;

ARTICLE; DATA BASE; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHARMACOLOGY; POLYPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHARMACOLOGY INTERACTION NETWORK DATABASE; VIRUS CELL INTERACTION;

EID: 84936776887     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.25     Document Type: Article

References (49)

1. Csermely, P., Korcsmáros, T., Kiss, H.J.M., London, G., &, Nussinov, R., Structure and dynamics of molecular networks: a novel paradigm of drug discovery: A comprehensive review. Pharmacol. Ther. 138, 333-408 (2013).
2. Csermely, P., Agoston, V., &, Pongor, S., The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 26, 178-182 (2005).
3. Pujol, A., Mosca, R., Farrés, J., &, Aloy, P., Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci. 31, 115-123 (2010).
4. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
5. Keiser, M.J., et al,. Predicting new molecular targets for known drugs. Nature 462, 175-181 (2009).
6. Paolini, G.V, Shapland, R.H.B., Hoorn, W.P. van, Mason, J.S., &, Hopkins, A.L., Global mapping of pharmacological space. Nat. Biotechnol. 24, 805-815 (2006).
7. Barabási, A.-L., Gulbahce, N., &, Loscalzo, J., Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56-68 (2011).
8. Azmi, A.S., Network pharmacology for cancer drug discovery: are we there yet? Future Med. Chem. 4, 939-941 (2012).
9. Espinoza-Fonseca, L.M., The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem. 14, 896-897 (2006).
10. Zimmermann, G.R., Lehár, J., &, Keith, C.T., Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
11. Chandra, N., &, Padiadpu, J., Network approaches to drug discovery. Expert Opin. Drug Discov. 8, 7-20 (2013).
12. Leung, E.L., Cao, Z.-W., Jiang, Z.-H., Zhou, H., &, Liu, L., Network-based drug discovery by integrating systems biology and computational technologies. Brief. Bioinform. 14, 491-505 (2013).
13. Rask-Andersen, M., Almén, M.S., &, Schiöth, H.B., Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590 (2011).
14. Harrold, J.M., Ramanathan, M., &, Mager, D.E., Network-based approaches in drug discovery and early development. Clin. Pharmacol. Ther. 94, 651-658 (2013).
15. Chavali, A.K., D'Auria, K.M., Hewlett, E.L., Pearson, R.D., &, Papin, J.A., A metabolic network approach for the identification and prioritization of antimicrobial drug targets. Trends Microbiol. 20, 113-123 (2012).
16. Goh, K., Cusick, M.E., Valle, D., Childs, B., Vidal, M., &, Barabási, A.-L., The human disease network. Proc. Natl. Acad. Sci. U. S. A. 104, 8685-8690 (2007).
17. Dudley, J.T., Schadt, E., Sirota, M., Butte, A.J., &, Ashley, E., Drug discovery in a multidimensional world: systems, patterns, and networks. J. Cardiovasc. Transl. Res. 3, 438-447 (2010).
18. Hu, Z., et al,. VisANT 4.0: integrative network platform to connect genes, drugs, diseases and therapies. Nucleic Acids Res. 41, W225-231 (2013).
19. Kim Kjærulff, S., et al,. ChemProt-2.0: visual navigation in a disease chemical biology database. Nucleic Acids Res. 41, D464-469 (2013).
20. Yamanishi, Y., Kotera, M., Moriya, Y., Sawada, R., Kanehisa, M., &, Goto, S., DINIES: drug-target interaction network inference engine based on supervised analysis. Nucleic Acids Res. 42, W39-45 (2014).
21. Hu, Q.-N., et al,. VNP: interactive visual network pharmacology of diseases, targets, and drugs. CPT Pharmacometrics Syst. Pharmacol. 3, e105 (2014).
22. Hu, Y., Wassermann, A.M., Lounkine, E., &, Bajorath, J., Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. J. Med. Chem. 53, 752-758 (2010).
23. Wang, Y., et al,. PubChem's bioassay database. Nucleic Acids Res. 40, D400-412 (2012).
24. Gaulton, A., et al,. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-1107 (2012).
25. Liu, T., Lin, Y., Wen, X., Jorissen, R.N., &, Gilson, M.K., BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35, D198-201 (2007).
26. Bemis, G.W., &, Murcko, M., The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887-2893 (1996).
27. Hu, Y., Stumpfe, D., &, Bajorath, J., Lessons learned from molecular scaffold analysis. J. Chem. Inf. Model. 51, 1742-1753 (2011).
28. Jiang, Y.-Y., Kong, D.-X., Qin, T., Li, X., Caetano-Anollés, G., &, Zhang, H.-Y., The impact of oxygen on metabolic evolution: a chemoinformatic investigation. PLoS Comput. Biol. 8, e1002426 (2012).
29. Bienfait, B., &, Ertl, P., JSME: a free molecule editor in JavaScript. J. Cheminform. 5, 24 (2013).
30. Hu, Y., &, Bajorath, J., Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J. Chem. Inf. Model. 50, 2112-2118 (2010).
31. Mysinger, M.M., Carchia, M., Irwin, J.J., &, Shoichet, B.K., Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582-6594 (2012).
32. Jewison, T., et al,. SMPDB 2.0: big improvements to the small molecule pathway database. Nucleic Acids Res. 42, 478-484 (2013).
33. Baltimore, D., Expression of animal virus genomes. Bacteriol. Rev. 35, 235-241 (1971).
34. Hulo, C., et al,. ViralZone: a knowledge resource to understand virus diversity. Nucleic Acids Res. 39, D576-582 (2011).
35. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L.J., &, Bork, P., Drug target identification using side-effect similarity. Science 321, 263-266 (2008).
36. Brouwers, L., Iskar, M., Zeller, G., Noort, V. van, &, Bork, P., Network neighbors of drug targets contribute to drug side-effect similarity. PLoS One 6, e22187 (2011).
37. Gershon, M., Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. 20, 3-14 (2004).
38. Hegde, S.S., &, Eglen, R.M., Peripheral 5-HT4 receptors. FASEB J. 10, 1398-1407 (1996).
39. Atreya, R.V., Sun, J., &, Zhao, Z., Exploring drug-target interaction networks of illicit drugs. BMC Genomics 14 Suppl 4, S1 (2013).
40. Knight, Z.A., Lin, H., &, Shokat, K.M., Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10, 130-137 (2010).
41. Finlayson, K., Witchel, H.J., McCulloch, J., &, Sharkey, J., Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 500, 129-142 (2004).
42. Hoffmann, P., &, Warner, B., Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 53, 87-105 (2006).
43. Roden, D.M., Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004).
44. Safety Alerts for Human Medical Products-Propulsid (cisapride) Dear Healthcare Professional Letter Apr 2000. < http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175000.htm > (2000).
45. Wermuth, C.G., Selective optimization of side activities: another way for drug discovery. J. Med. Chem. 47, 1303-1314 (2004).
46. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., &, Hirakawa, M., KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355-360 (2010).
47. Law, V., et al,. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-1097 (2014).
48. Zhu, F., et al,. Update of TTD: therapeutic target database. Database 38, 787-791 (2010).
49. Keiser, M.J., Roth, B.L., Armbruster, B.N., Ernsberger, P., Irwin, J.J., &, Shoichet, B.K., Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206 (2007).